Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme Academic Article uri icon


MeSH Major

  • Biomarkers, Tumor
  • Brain Neoplasms
  • Glioblastoma
  • Neovascularization, Pathologic


  • These studies suggest that plasma and circulating CD133+ vascular endothelial growth factor receptor 2+ proangiogenic cells are present in the peripheral blood of patients with glioma and can be used as a surrogate biomarker to measure tumor angiogenicity. These cells can be measured at the time of diagnosis and monitored in the postoperative period. These assays can be used to predict tumor aggressiveness. Also promising is their potential to identify patients with increased angiogenic activity who might respond maximally to antiangiogenesis therapies or to assess tumor response in patients using those therapies as the use of these adjuvant molecular modalities becomes more prevalent in neuro-oncology.

publication date

  • May 2009



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1227/01.NEU.0000343742.06625.DB

PubMed ID

  • 19404145

Additional Document Info

start page

  • 819

end page

  • 26; discussion 826-7


  • 64


  • 5